Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Stock Up 7.4%

Shares of Structure Therapeutics stock opened at $17.51 on Tuesday. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $45.37. The company’s 50-day simple moving average is $19.70 and its 200-day simple moving average is $21.69. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -16.68 and a beta of -1.89.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several recent analyst reports. JMP Securities lowered their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, June 23rd. Citigroup initiated coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 target price on the stock. Guggenheim lowered their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Finally, HC Wainwright lowered their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $75.71.

Institutional Trading of Structure Therapeutics

An institutional investor recently raised its position in Structure Therapeutics stock. Geode Capital Management LLC grew its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 18.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,181 shares of the company’s stock after purchasing an additional 8,444 shares during the quarter. Geode Capital Management LLC owned approximately 0.09% of Structure Therapeutics worth $1,124,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.